Apollo Therapeutics

Apollo Therapeutics company information, Employees & Contact Information

Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo’s portfolio-based model combines a centralized team of drug development ‘architects’ and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner – prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease. Apollo’s innovative model was created in late 2015 by three world-leading universities Cambridge, Imperial College London and University College London in partnership with AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation. There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development. We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners. Apollo is funded by Patient Square Capital, Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. We are expanding our operations in Cambridge, UK and Boston, USA. For more information, please visit our website at www.apollotherapeutics.com
Looking for a particular Apollo Therapeutics employee's phone or email?

Apollo Therapeutics Questions

News

Apollo Therapeutics - Business Weekly

Apollo Therapeutics Business Weekly

Apollo Therapeutics Announces Second Close of Series C Financing Bringing Total Raised in Round to $260 Million - Business Wire

Apollo Therapeutics Announces Second Close of Series C Financing Bringing Total Raised in Round to $260 Million Business Wire

Ropes & Gray Advises Apollo Therapeutics on Exclusive Ex-China License for Clinical-Stage FGF21/GLP-1 Dual Receptor Agonist - Ropes & Gray LLP

Ropes & Gray Advises Apollo Therapeutics on Exclusive Ex-China License for Clinical-Stage FGF21/GLP-1 Dual Receptor Agonist Ropes & Gray LLP

Apollo Therapeutics Closes $226.5 Million Series C Financing Led by Patient Square Capital - BeBeez International

Apollo Therapeutics Closes $226.5 Million Series C Financing Led by Patient Square Capital BeBeez International

Latham Advises on Apollo Therapeutics’ US$226.5 Million Series C Financing - Latham & Watkins LLP

Latham Advises on Apollo Therapeutics’ US$226.5 Million Series C Financing Latham & Watkins LLP

Apollo Therapeutics raises $226.5m to develop medicines based on uni research - Imperial College London

Apollo Therapeutics raises $226.5m to develop medicines based on uni research Imperial College London

Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics - GlobeNewswire

Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics GlobeNewswire

Apollo Therapeutics and Oxford University enter into drug discovery and development collaboration - University of Oxford

Apollo Therapeutics and Oxford University enter into drug discovery and development collaboration University of Oxford

Apollo Therapeutics takes Series C round to $260M for advancing University research-based medicines - Tech Funding News

Apollo Therapeutics takes Series C round to $260M for advancing University research-based medicines Tech Funding News

Apollo Therapeutics receives $226.5 million to fund medical research - King's College London

Apollo Therapeutics receives $226.5 million to fund medical research King's College London

UCL partner Apollo Therapeutics receives $226.5m to translate medical research into treatments - University College London

UCL partner Apollo Therapeutics receives $226.5m to translate medical research into treatments University College London

Apollo Therapeutics secures $226.5 million to translate fundamental research into medicines - University of Cambridge

Apollo Therapeutics secures $226.5 million to translate fundamental research into medicines University of Cambridge

Apollo Therapeutics closes $226.5 million series C financing - Taylor Wessing

Apollo Therapeutics closes $226.5 million series C financing Taylor Wessing

Apollo lands inflammatory antibody from Avalo for $90M biobucks - Fierce Biotech

Apollo lands inflammatory antibody from Avalo for $90M biobucks Fierce Biotech

Apollo Therapeutics launches with £100m investment - University of Cambridge

Apollo Therapeutics launches with £100m investment University of Cambridge

UCL joins consortium to launch £40 million Apollo Therapeutics Fund | UCL News - UCL - University College London

UCL joins consortium to launch £40 million Apollo Therapeutics Fund | UCL News - UCL University College London

King's College London and Apollo Therapeutics enter into a strategic collaboration - King's College London

King's College London and Apollo Therapeutics enter into a strategic collaboration King's College London

Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Advance Portfolio-Based Drug Development - Business Wire

Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Advance Portfolio-Based Drug Development Business Wire

Top Apollo Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant